Abiraterone Acetate (Zytiga™) Tablet - Review and revision to guideline; consisting of description section, position statement to include continuation criteria, dosage/administration, definitions, and references.
Cabazitaxel (Jevtana®) Injection - Review and revision to guideline; consisting of description, position statement, related guidelines, and updating of references.
Computed Tomography (CT) Thorax (Chest) - Revised description. Deleted pulmonary embolism and pre-operative evaluation. Revised: tumor, cancer or mass, infection or inflammatory disease, vascular disease, congenital abnormalities, hemoptysis, post-operative evaluation and add “procedural” to header, and other. Added: indication for combination studies for initial pre-therapy staging of cancer, or ongoing tumor/cancer surveillance, or evaluation of suspected metastases, combination studies with chest CT, and combination of studies with chest CT/sinus CT.
Pertuzumab (Perjeta™) Injection - Review and revision to guideline; consisting of revising position statement, references, definitions, program exceptions.
Preventive Services - Revision; revised statement for chlamydia screening (women), dental caries, gonorrhea screening (women), and sexually transmitted infection counseling. Added statement regarding application of fluoride varnish to infants and children teeth. Added 87624, 87625, and 99188. Revised headers for dental caries prevention and healthy diet counseling. Added heading and statement for healthy diet and physical counseling to prevent cardiovascular disease (adults with cardiovascular risk factors). Added statement for preeclampsia prevention (aspirin). Added related guidelines. Updated references.